NRX Pharmaceuticals, Inc. 8-K

What Happened

• NRX Pharmaceuticals, Inc. announced a public offering and entered into an underwriting agreement with BTIG, LLC as representative of the underwriters. The company sold 5,714,286 shares of common stock at $3.50 per share. The offering closed on June 4, 2026.
• The Underwriters have a 30-day option to purchase up to 857,142 additional shares. The offering was made under the company’s Form S-3 shelf registration declared effective December 22, 2025. The company issued press releases on June 3 and June 4, 2026 announcing the pricing and closing.

Key Details

• Shares sold: 5,714,286 common shares at $3.50 per share.
• Underwriter option: 30 days to buy up to 857,142 additional shares.
• Estimated net proceeds: approximately $18.8 million (or $21.6 million if the option is fully exercised), after fees and expenses.
• Lock-up: the company and its directors and executive officers agreed not to sell or transfer common stock without underwriter consent for 60 days.

Why It Matters

• This financing provides NRX with fresh capital (roughly $18.8M net today, more if the option is exercised), which can support operations, development programs, or balance-sheet needs.
• The 60-day lock-up and customary underwriting arrangements (including indemnities) are standard protections for the offering and may limit insider selling in the short term.
• Investors should note the potential dilution from the base offering and any exercise of the underwriter option; examine company communications for intended use of proceeds and any updates on clinical or business milestones.